Skip to main content

Theravance Biopharma, Inc.

TBPH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001583107

In the last 90 days, Theravance Biopharma, Inc. insiders filed 0 open-market purchases and 3 sales; 179 institutions reported holding it in 13F filings for Q2 2026, worth $817.5M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Theravance Biopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
2 insiders, $6.14M in total
Insiders trading
2
Net value
−$6.14M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Theravance Biopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Theravance Biopharma, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Pakianathan DeepikaDirector0Sep 24, 20262
O'Connor DonalDirector0Sep 24, 20262
Mitchell Dean JDirector0Sep 24, 20262
Gray SusannahDirector0Sep 24, 20262
Smaldone Alsup LaurieDirector0Sep 24, 20262
Winningham Rick ECHIEF EXECUTIVE OFFICER0IndirectSep 24, 20266
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER0Sep 24, 20266
Miller AineSVP, DEV & HEAD OF IRE OFFICE0Sep 24, 20266
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY0Sep 24, 20266
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS0Sep 24, 202610
Samaha Eli10% Owner9,167,489IndirectJul 8, 20262
Broshy EranDirector44,703Dec 1, 20252
Grant Jeremy TDirector32,954May 21, 20250
Graham Richard ASVP, RESEARCH & DEVELOPMENT314,915Feb 22, 20240
Malkiel Burton GDirector100,589May 4, 20230
Hindman Andrew A.SVP, CHIEF FINANCIAL OFFICER384,714Nov 22, 20220
GlaxoSmithKline PLCOther: Former 10% Owner0IndirectSep 20, 20220
Young William DDirector78,010Apr 28, 20220
Pitzer Kenneth RSVP, PROD STRAT & COMM PLNG380,123Feb 23, 20220
Brady AnnPRESIDENT, TBIL110,319Feb 23, 20220
Pasqualone FrankSVP, CHIEF BUSINESS OFFICER429,783Nov 23, 20210
Worboys Philip DSVP, RESEARCH & TRANSL SCIENCE330,752Nov 23, 20210
Sabesan VijaySVP, TECHNICAL OPERATIONS235,524Nov 23, 20210
Shafer Bradford JEVP, Gen. Counsel, Secretary277,831Aug 24, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 17, 2026 (view filing)5:52 PM ETSep 152 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−13.3K$17.03−$226.8K−5.9%213.5K after3 lots10b5-1
Jul 8, 2026 (view filing)4:13 PM ETJul 6-72 daysSamaha Eli10% OwnerSSaleCOM−6.96K$17.14−$119.4K−0.1%9.17M after2 lots
Jul 1, 2026 (view filing)7:33 PM ETJun 29-Jul 12 daysSamaha Eli10% OwnerSSaleCOM−336.7K$17.20−$5.79M−3.5%9.17M after3 lots
Jun 17, 2026 (view filing)Jun 152 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−13.3K$16.39−$218.2K−5.4%232.5K after3 lots10b5-1
Mar 18, 2026 (view filing)Mar 162 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−31.1K$13.96−$433.7K−11.8%232.7K after3 lots10b5-1
Dec 5, 2025 (view filing)Dec 32 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−31.1K$18.75−$582.5K−10.1%277.7K after3 lots10b5-1
Dec 1, 2025 (view filing)Nov 265 daysBroshy EranDirectorSSale−29.5K$20.00−$590.0K−39.8%44.7K after2 lots10b5-1
Nov 14, 2025 (view filing)Nov 113 daysBroshy EranDirectorSSale−45.0K$17.98−$809.3K−42.8%60.2K afterAmended3 lots
Jul 16, 2025 (view filing)Jul 142 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−10.0K$11.39−$113.9K−3.0%326.9K after3 lots10b5-1
Jun 4, 2025 (view filing)Jun 22 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−24.0K$11.00−$264.0K−6.6%336.9K after10b5-1
Apr 23, 2025 (view filing)Apr 212 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−4.00K$9.00−$36.0K−1.1%370.0K after10b5-1
Jan 23, 2025 (view filing)Jan 212 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−4.00K$9.00−$36.0K−1.3%309.6K after10b5-1
Nov 13, 2024 (view filing)Nov 112 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−4.00K$9.00−$36.0K−1.2%322.7K after
Aug 9, 2024 (view filing)Aug 72 daysSamaha Eli10% OwnerPPurchaseCOM+999.8K$7.80+$7.80M+11.7%9.51M after
Jul 12, 2024 (view filing)Jul 102 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−4.00K$9.00−$36.0K−1.2%336.0K after10b5-1
May 3, 2024 (view filing)May 12 daysSamaha Eli10% OwnerPPurchaseCOM+1.50M$8.75+$13.1M+21.4%8.51M after2 lots
Feb 22, 2024 (view filing)Feb 22Same dayFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−1.25K$8.71−$10.9K−0.4%311.7K after10b5-1
Nov 22, 2023 (view filing)Nov 211 dayFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−1.38K$10.29−$14.2K−0.4%331.2K after10b5-1
Nov 16, 2023 (view filing)Nov 142 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.48K$10.22−$25.4K−0.7%346.8K after10b5-1
Oct 18, 2023 (view filing)Oct 162 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.48K$9.03−$22.4K−0.7%334.3K after10b5-1
Sep 18, 2023 (view filing)Sep 144 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.48K$9.89−$24.5K−0.7%336.8K after10b5-1
Aug 24, 2023 (view filing)Aug 222 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−1.81K$9.47−$17.1K−0.5%340.6K after10b5-1
Aug 15, 2023 (view filing)Aug 114 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.32K$9.99−$23.2K−0.7%349.7K after10b5-1
Jul 18, 2023 (view filing)Jul 144 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.32K$9.84−$22.8K−0.7%352.1K after
Jun 16, 2023 (view filing)Jun 142 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.32K$10.69−$24.8K−0.7%354.4K after
Jun 12, 2023 (view filing)Jun 84 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−1.79K$11.13−$19.9K−0.5%352.8K after
May 17, 2023 (view filing)May 152 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.32K$11.26−$26.1K−0.6%367.2K after
Apr 18, 2023 (view filing)Apr 144 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.32K$11.88−$27.6K−0.6%369.5K after
Mar 16, 2023 (view filing)Mar 142 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.32K$10.32−$24.0K−0.6%371.8K after
Mar 13, 2023 (view filing)Mar 94 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−4.00K$10.20−$40.8K−1.1%360.2K after
Mar 8, 2023 (view filing)Mar 62 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.32K$10.05−$23.3K−0.6%374.1K after
Dec 16, 2022 (view filing)Dec 142 daysWinningham Rick ECHIEF EXECUTIVE OFFICERSSale−50.0K$11.19−$559.5K−3.6%1.35M after
Dec 5, 2022 (view filing)Dec 14 daysGraham Richard ASVP, RESEARCH & DEVELOPMENTSSale−2.08K$10.73−$22.4K−0.7%313.5K after
Nov 22, 2022 (view filing)Nov 184 daysHindman Andrew A.SVP, CHIEF FINANCIAL OFFICERSSale−65.0K$11.02−$716.3K−13.7%409.8K after
Aug 18, 2022 (view filing)Aug 162 daysGraham Richard ASVP, DEVELOPMENTSSale−4.91K$9.71−$47.6K−1.3%364.7K after
Aug 11, 2022 (view filing)Aug 92 daysGraham Richard ASVP, DEVELOPMENTSSale−15.1K$8.79−$132.6K−3.9%369.7K after
May 24, 2022 (view filing)May 231 dayFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−1.08K$8.93−$9.65K−0.3%330.0K after
Mar 2, 2022 (view filing)Feb 282 daysFarnum RhondaSVP, COMM & MEDICAL AFFAIRSSSale−2.36K$10.16−$23.9K−0.7%333.3K after